---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-007042"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:14:58.215710+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics reports positive proof-of-concept study results in Frontotemporal Dementia

## Summary
- 9-patient open-label study of low-dose IL-2 + CTLA4-Ig showed no serious adverse events over 22 weeks.
- Treg suppressive function and percentage significantly increased from week 2 through week 22.
- MOCA scores stable (baseline 13.5, week 22: 14) and CDR-FTLD stable (4.8 vs 5.5), indicating no cognitive decline.
- Study led by Houston Methodist Neurological Institute; funded by Peggy and Gary Edwards Endowment Fund.
- Common adverse event was mild injection-site erythema (33.3%); all resolved spontaneously.

## SEC filing metadata
- accession: 0001193125-26-007042
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312526007042/0001193125-26-007042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312526007042/d39008d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-007042
- JSON: https://secwatch.observer/filing/0001193125-26-007042.json
- Plain text: https://secwatch.observer/filing/0001193125-26-007042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.